Junevity is a biotechnology company developing cell reprogramming therapeutics with siRNA. The Junevity RESET platform is the first to use human disease omics, genetic linkages and ML/AI to identify novel transcription factor targets and repress them with siRNA therapeutics. Initial programs are in metabolism and neurodegeneration. Based in San Francisco and founded out of UCSF in 2023, Junevity's mission is to increase lifespan and healthspan.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/03/25 | $20,000,000 | Seed |
Godfrey Capital Goldcrest Capital | undisclosed |
